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Background: Improved survival rates in early breast cancer and the chronic nature of disease relapse result in a
large cohort of patients being available for long-term follow-up (LTFUP) in randomised controlled trials. Whilst of
recognised scientific value to assess long-term treatment-related sequelae, the volume of this activity can be
challenging for trialists and participating sites, and comes at a considerable cost to research funders and the
National Health Service (NHS). A National Cancer Research Institute Breast Clinical Studies Group supported project
aimed to characterise UK LTFUP data collection procedures in order to propose improvements.
Methods: Protocols and case report forms for UK non-commercial National Institute for Health Research portfolio
early breast cancer randomised controlled trials were reviewed and a questionnaire sent to associated participating
NHS sites. Responders were asked to give opinions on issues with follow-up and LTFUP data collection procedures
and to suggest potential improvements to practice. Results were used to inform design of a proposed standard
LTFUP case report form.
Results: Thirty-four trials, involving eight Clinical Trials Units were eligible for inclusion in the review. All trials
requested follow-up at least annually up to 5 years, with two-thirds requesting LTFUP after that time point.
Information relating to efficacy endpoints was captured for all trials via case report forms; however, precise detail
on recording of recurrence, second malignancies and death varied. Separately, questionnaires were returned from
66 NHS sites. Main concerns identified included difficulties in identifying all adverse events from hospital notes,
volume of work, bureaucratic data management practices in Clinical Trials Units and perceptions of prioritisation of
recruitment over follow-up.
Conclusion: Variation has existed with respect to detail of LTFUP information requested for UK trials. Improved
communication, simplification and standardisation of data and associated collection methods are possible without
compromising data requirements for efficient and effective trial reporting. Future use of routinely collected data,
captured via electronic means, could transform practices and alleviate resource usage.
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A consequence of the welcome improvement in the sur-
vival rates from selected cancers [1] is the increase in the
number of patients available for long-term follow-up
(LTFUP) in randomised controlled trials (RCTs), thus en-
abling further evaluation of long-term treatment-related
sequelae beyond the time of primary analysis. Collation
of existing evidence from historical trials in the form of
meta-analysis (for example, by the Early Breast Cancer
Trialists’ Collaborative Group) has illustrated that clinically
important effects may only become apparent 10 or even
20 years after treatment was delivered. In particular, trials
investigating the addition of radiotherapy have demon-
strated clinically worthwhile effects on long-term outcome
from breast cancer; however, they have also identified an
apparent excess risk of non-breast cancer deaths, most
notably from cardiovascular disease. In both cases, di-
vergence between the treatment groups did not begin to
emerge until many years after treatment [2]. In terms of
systemic therapy for breast cancer, the full potential of
tamoxifen was not in fact observed until 10 years after ran-
domisation [3]. Conversely, possible carcinogenic risks as-
sociated with cytotoxic therapy for breast cancer may not
be expected to be seen for many years after treatment.
Therefore, whilst an analysis at or around 5 years follow-
up may be reasonable to provide an initial estimate of
treatment effect on disease-free survival, lack of LTFUP
beyond that point misses the opportunity to characterise
whether such beneficial effects of treatment translate into
improvements in overall survival, and also incurs the risk
of failing to detect potential longer term safety issues.
Given the large number of patients worldwide pre-
scribed cancer treatment on the basis of trial evidence,
trialists including those conducting breast cancer trials
have a responsibility to ensure that trials report full and
unbiased evidence on both the safety and efficacy of trial
treatments. This requires follow-up of trial patients for
many years after they have completed their treatment
which inevitably incurs work for both sites recruiting pa-
tients into trials and Clinical Trials Units (CTUs) col-
lecting and analysing the data.
Phase III trials in early breast cancer typically recruit
3,000 to 4,000 patients and utilise disease-free survival
as their primary endpoint (a composite of local, distant
relapse and death) analysed via survival analysis methods
at a follow-up of about 5 years. With recruitment likely
to be ongoing for 3 to 5 years, a decade can often elapse
between the time a funding application is submitted and
the time point when the majority of patients become
eligible for LTFUP. Considerable changes can have oc-
curred in expectations and practices of funders and
health services during that time period and the propor-
tion of patients surviving and available for LTFUP may
be more than originally expected due to concurrentgeneral improvements in patient care and associated
outcomes.
Thus, the issues associated with the current follow-up
and in particular LTFUP activity of trial patients are
twofold. First, the number of UK patients entered into
trials who continue in follow-up is now extensive. For
example, over 13,000 UK patients were recruited to the
National Epirubicin Adjuvant Trial (NEAT), Adjuvant
Breast Cancer (ABC), Taxotere as Adjuvant Chemother-
apy (TACT), Intergroup Exemestane Study (IES), and
Standardisation of Breast Radiotherapy (START) breast
cancer trials, and the approximate percentages of partici-
pants surviving at 5 years after randomisation for these
trials are 79%, 78%, 82%, 90%, and 89%, respectively.
Thus, completion of follow-up and LTFUP case report
forms (CRFs) is a considerable resource activity for
research staff in participating sites. Similarly, the CTUs
continue to employ data management staff to oversee
receipt of follow-up and LTFUP data, requiring funding
for a dedicated resource lasting for many years after a
trial has reported its principal results. Historically this
work has been largely unquantified. As the volume of
work has increased, however, given the growth in the
number of trials being undertaken and the improved
survival rates observed, together with the fact that over-
sight of trial activities in both CTUs and participating
sites is more heavily scrutinised, a concern has grown as
to the potential burden of associated work leading to the
need to quantify the current activity and to ensure
procedures are efficient and appropriate to justify the
continued resource dedicated to this activity. Second, as
National Health Service (NHS) clinical practice changes,
more patients are being discharged earlier from oncol-
ogy care. Hence, the ability of participating sites to refer
to routine data sources (for example, hospital records) in
order to obtain the requisite follow-up information is
increasingly threatened and requires participating sites
to chase individual patients via General Practitioners
(GPs) or contact the patients themselves, potentially
causing unnecessary distress.
In the UK, clinical trial investigators and CTUs have
been aware of the opportunities and challenges associ-
ated with follow-up and in particular LTFUP for many
years and advocate minimising data collection require-
ments to ease some of the burden on participating sites.
One such way trial teams are trying to reducing this bur-
den is by collecting patient identifiers at trial entry, with
patient consent, to enable use of tracing systems and
with a desire in future to link with routinely available
datasets - for example, cancer registry data. However,
each trial also traditionally has bespoke CRFs with for-
mat, data collection items and the frequency of follow-
up having the potential to vary between trials. Anecdotal
evidence suggested some trials, both newer and older,
Table 1 List of all trials present on the National Institute
for Health Research trials portfolio in 2008 eligible for
the review of Clinical Trials Unit current practice
• ACTION • PERSEPHONE
• ALTTO • POETIC
• ATTOM • PRIME
• AZURE • PRIME II
• COMICE • REACT
• DEVA • SECRAB
• EORTC 10981 • SOFT
• ESTEEM • START
• FAST • SUPREMO
• HERA • TACT
• HRT • TACT2
• IMPORT HIGH • TANGO
• IMPORT LOW • TEAM
• NEAT • TEXT
• NEO EXCEL • TOPIC
• NEO TANGO • TOPIC2
• NEOCENT • TRAFIC
Kilburn et al. Trials 2014, 15:379 Page 3 of 10
http://www.trialsjournal.com/content/15/1/379were requesting surplus information or data that is almost
impossible to retrieve within sites and at too frequent in-
tervals. In addition, it has been recognised that the balance
between minimising losses to follow-up and timely collec-
tion of important clinical information needs to be identi-
fied and consideration given to the actual information
requested and its impact. For example, standardised re-
cording of normal tissue damage after radiotherapy is not
routinely available in oncology notes but is essential for
evaluation of normal tissue cosmetic outcomes; therefore,
the additional resource required to collect these data
manually can be justified. Alternatively, collecting data
on hospitalisations for patients during LTFUP may not
be cost-effective, especially as these events are unlikely
to be associated with treatment sequelae, are likely to
occur in hospitals other than the follow-up site and, as a
consequence, result in data of questionable complete-
ness and validity.
Here, the results of a project, funded by the National
Institute for Health Research (NIHR) National Cancer Re-
search Network (NCRN) and National Cancer Research
Institute (NCRI) and conducted on behalf of the NCRI
Breast Clinical Studies Group are reported. The aims of
the project were to characterise the type and quantify the
volume of LTFUP activity in non-commercial, academic-
led RCTs in early breast cancer. The project included a
protocol and CRF review to determine current practices
in RCT data collection and a questionnaire to NHS par-
ticipating sites.
Methods
Protocol and case report form review
Trials eligible for the protocol and CRF review were
those early breast cancer RCTs which were listed on the
NIHR portfolio in 2008 (Table 1). Trials were included if
they were designed to investigate the effects of neoadju-
vant or adjuvant therapy, systemic therapy or radiother-
apy and where recurrence (as assessed via disease-free
survival or similar endpoint) or survival was a primary
or secondary endpoint. Such trials would routinely be
expected to collect data over many years and to continue
to quantify disease outcomes and risks beyond the time
of the analysis of primary endpoint.
For each trial identified, the relevant CTU responsible
for central management of the trial and Chief Investigator
were contacted and asked to send trial protocols and CRFs
for review. Data was extracted for each trial to characterise
the trial’s follow-up and LTFUP data requirements. Data
extraction was conducted using a five-page proforma
which aimed to extract relevant information such as
frequency of data collection, patient identifiable data col-
lected at baseline and efficacy and adverse event (AE)
question definitions (Additional file 1: Figure A1). Statis-
tical analysis was descriptive in nature, and summarised intabular and graphical form. Unless otherwise stated, all in-
formation was taken from the (repeating) follow-up form
only (for example, recurrence information requested on
follow-up form only, regardless of whether information is
requested again on a separate one-off recurrence form).
Questionnaire to National Health Service participating
sites
Subsequent to the protocol and CRF review, a decision
was made to develop a questionnaire to send to NHS
participating sites to ascertain a better understanding of
the issues relating to LTFUP in breast cancer trials from
a site perspective.
In November 2009, a questionnaire was distributed via
the NCRN and their research network managers to NHS
participating sites. This method of distribution aimed to
ensure a co-ordinated approach and optimise return
rates (Additional file 1: Figure A2); however, this results
in an unknown denominator in terms of number of sites
surveyed. Given that the project was a survey of NHS
staff in their professional role, ethical approval was not
required. The survey requested that the questionnaire be
completed in relation to experiences of non-commercial,
academic-led breast cancer clinical trials on the NIHR
portfolio only, by any person responsible for completing
follow-up forms associated with such trials. A general
reminder email was sent to encourage sites to return
questionnaires. Responses were assessed on a site-by-site
basis. The questionnaire asked about routine practice in
sites and accessibility of data items currently requested
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tunity to give opinions on issues with LTFUP data col-
lection in their participating site, issues with electronic
follow-up and to propose any solutions they considered
helpful. Qualitative free text answers were assessed for
key themes.Definition of long-term follow-up
There is no standard definition for “follow-up” or
“LTFUP” in RCTs. Therefore, for this project “follow-up”
was defined as visits/contact subsequent to completion
of surgery/radiotherapy/chemotherapy treatment and
“LTFUP” as visits/contact >5 years after randomisation.
Follow-up at participating sites is normally conducted
via patients attending an outpatient appointment or staff
at participating sites, a request to the patient’s GP or by
contacting the patient by telephone.Quantifying the volume of activity associated with
long-term follow-up
To represent the volume of activity in the UK of following
up breast cancer trial patients >5 years after randomisa-
tion, the number of patients previously entered into NIHR
portfolio RCTs and continuing to be followed-up was esti-
mated by year. This was calculated using annual recruit-
ment rates in the UK up to the end of 2009 for trials
eligible for protocol and CRF review (see below) and 5-
year survival rates for these trials if available (or an ap-
proximation if not). It also assumed an approximate lost



















Figure 1 Growth in UK patients predicted to be in long-term follow-u
included in the review. It is expected that approximately 27,000 patients wResults of the data extraction from protocols and CRFs
and quantitative responses in the questionnaires returned
from participating sites were collated via entry into an
Access database (Microsoft Corporation, Redmond, WA.
USA). All statistical analyses were conducted using Stata
version 10 (StataCorp, College Station, Texas, USA).Results
Thirty-four trials were deemed eligible to be included in
the protocol and CRF review. Whilst these trials repre-
sent a cross-section of NIHR portfolio trials it can be as-
sumed that, for trials included in the review, the number
of patients in LTFUP would have reached steady state in
2013 when approximately 27,000 patients in the UK
would have been >5 years after randomisation and still
available for follow-up (Figure 1). This number would be
expected to decline gradually over the next few years
due to a small number of patients dying or becoming
unavailable for follow-up each year.Protocol and case report form review
Of the 34 eligible trials, only two trials declined to pro-
vide CRFs for the project and information for these trials
was obtained from the protocol only. Standard adjuvant
therapy trials evaluating chemotherapy, endocrine ther-
apy and/or radiotherapy comprised nearly two-thirds of
the trials in the review, with the minority remainder
including trials of targeted therapies and neoadjuvant/
perioperative treatment - the more recent focus of the
NIHR breast cancer portfolio (Figure 2).2006 2007 2008 2009 2010 2011 2012 2013 2014
f follow up
p (>5 years after randomisation). Thirty-four national trials were





















Trial by type of adjuvant
treatment 
Figure 2 National trials included in the review. Data on the type of adjuvant treatment was taken from either the protocol or case
report form.
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Nearly all of the trials collected date of birth (32/34
(94.1%)) and hospital number (29/34 (85.3%)) with just
under three-quarters collecting the full patient name
(25/34 (73.5%)). NHS number, the key data item used
for identifying patients in registry data, was only col-
lected in approximately half of the trials (18/34 (52.9%))
(Additional file 1: Figures A3a,b). As a consequence of
collecting patient identifiers, 21 (64%) trials stated they
are intending to use tracing services to facilitate follow-
up of patients in the long term.
Timing of follow-up
Nearly all trials aim to collect information on the anni-
versary of randomisation at years 1 and 2 (year 1 = 32/34
(94.1%); year 2 = 33/34 (97.1%)), with half of the trials
requesting intermediate follow-up data at 18 months
(17/34 (50.0%)). A similar pattern is present between
years 2 and 5, with all trials collecting data annually
(from year 2 = 33/34 (97.1%); from years 3 to 5 = 34/34
(100.0%)) and a few trials collecting data in between at
2.5 and 4.5 years (2.5 years = 14/34 (41.2%); 4.5 years =
8/34 (23.5%)). Annual data collection continues between
years 5 and 10. Approximately two-thirds of trials (22/34
(64.7%)) state an intention to collect data routinely
beyond 5 years (Additional file 1: Figures A4a-c).
Efficacy data
All trials collected some information on efficacy data on
the follow-up form. The patient’s vital status was col-
lected in 31 (91.2%) trials, while the date the patient was
last seen or contacted was collected for 32 (94.1%) trials;26 (76.5%) trials requested that the patient was seen in
person, 3 (8.8%) allowed the patient to be seen or con-
tacted and 3 (8.8%) did not specify. Disease outcome sta-
tus, including date of death, local/distant recurrence and
second primary details, were requested on 21 (61.8%), 32
(94.1%) and 24 (70.6%) of follow-up forms, respectively,
with some requesting an additional recurrence/death
form be completed as appropriate. Other trials took a
reactive approach and required completion of separate
recurrence/death forms only when an event occurred.
Five (14.7%) trials requested death certificates or autopsy
reports from participating sites and 3 (8.8%) routinely
collected pathology and radiology reports for recurrence
or second primary events. In addition, half the trials
(17/34) collected details on treatment after relapse.Safety information on follow-up form
The collection of data relating to safety and occurrence of
AEs was varied (Table 2) with data requested on specific
types of AEs via tick boxes, often using Common Toxicity
Criteria for Adverse Events, or Radiation Therapy Oncol-
ogy Group grading, by the type of investigational treat-
ment. Endocrine therapy trials most commonly collected
information on cardiovascular, musculoskeletal and gyna-
ecological events. Radiotherapy trials collected cardiovas-
cular events and fractures. All trials allowed a free-text
space to provide information on “other” toxicity. Seven
trials collected data relating to patient hospitalisations dur-
ing LTFUP as a free-text option; three collected hospital
admissions only while the remaining four also requested
details on specific AEs.
Table 2 Number of trials recording adverse events by type of treatment
Chemotherapy Endocrine therapy Radiotherapy Neoadjuvant/perioperative therapy Other All
Cardiovascular 3 (38%) 4 (50%)* 5 (71%)* 0 (0%) 2 (33%) 14 (41%)
Neurological 1 (13%) 2 (25%) 0 (0%) 0 (0%) 2 (33%) 5 (15%)
Menopausal 0 (0%) 3 (38%) 0 (0%) 0 (0%) 0 (0%) 3 (9%)
Fracture 1 (13%) 4 (50%)* 5 (71%)* 0 (0%) 1 (17%) 11 (32%)
Other musculoskeletal 1 (13%) 4 (50%)* 2 (29%) 0 (0%) 0 (0%) 7 (21%)
Psychiatric 0 (0%) 2 (25%) 0 (0%) 0 (0%) 0 (0%) 2 (6%)
Gastrointestinal 0 (0%) 3 (38%) 0 (0%) 0 (0%) 0 (0%) 3 (9%)
Gynaecological 0 (0%) 4 (50%)* 0 (0%) 0 (0%) 0 (0%) 4 (12%)
Other (free text) 6 (75%)* 6 (75%)* 5 (71%)* 3 (60%)* 4 (67%)* 24 (71%)*
Hospitalisations (free text) 3 (38%) 2 (25%) 0 (0%) 0 (0%) 2 (33%) 7 (21%)
*Greater than or equal to 50% of trials requested details.
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Questionnaires were returned from 66 UK NHS partici-
pating sites. The majority of the questionnaires were com-
pleted by research nurses and data managers responsible
for completing trial CRFs at the participating site. The me-
dian number of academic-led early breast cancer (EBC)
RCTs running per site was 11.5 (interquartile range: 8
to 14). Clinics run specifically to follow-up trial patients
were available in 13/66 (19.7%) sites. Of those sites that did
not have specific follow-up clinics, 17 (32.1%) have consi-
dered setting one up, with the main reason for not having
set up one being lack of space/time (n = 9) and awaiting
decision/outcome of trial (n = 5). Of those sites that have

















Figure 3 Information available on hospital electronic patient record s
Additional file 1: Figure A1). ICD10, International Classification of Diseases-1
Nomenclature of Medicine Clinical Terms.Responders also indicated what information was avail-
able on their local electronic patient record systems
(Figure 3). Access to clinical coding systems (for ex-
ample, Systematized Nomenclature of Medicine Clinical
Terms, International Classification of Diseases-10, Operat-
ing Procedure Codes-4) was limited, and approximately
half the responders had electronic access to relapse and
second primary cancer information and date of death
easily available, but cause of death was more difficult to
ascertain. In addition, the majority of responders stated
that hospital admissions and toxicity data were only ac-
cessible if they were reported in the same NHS Trust. AEs
were not reported systematically either electronically or
on paper records.No Yes
f information
ystems. Data were obtained from returned questionnaires (see
0; OPCS4, Operating Procedure Codes-4; SNOMED CT, Systematized
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common themes. Main concerns included difficulties in
identifying all AEs, volume of work, bureaucratic data
management practices in CTUs and perceptions of
prioritisation of recruitment over follow-up (see below).
General issues with long-term follow-up collection in breast
cancer trials – key themes
 Lack of time/follow-up patient visits rescheduled
 Lack of personnel/staffing issues (for example,
continuity of staff )
 Lack of tracking database/electronic systems
 GPs uncooperative
 Lack of space to store CRFs/archiving
 (Early) discharge of patients
 Transfer of patients to another hospital/lack of
integrated electronic patient records system in UK
 Information detailed in patient notes inadequate
 Volume of patients in clinics
 CTUs sending large batches of requests at one time
 CTUs sending requests for really old data
 CTUs expecting a short turnaround for requests
 Lack of response from other departments within
same hospital (for example, histopathology)
 CTUs creating complex CRFs with unnecessary
information/too many pages
 CTUs creating new (additional) CRFs (for example,
TACT Herceptin form)
 Patients not turning up for follow-up visits (for example,
not interested, feeling well or parking/travel costs)
 Research and development departments and
consultants not taking into account work required for
follow-up when agreeing to take part in new trials
 CTUs not talking to one another when sending out
large requests
 NCRN priorities e.g. recruitment over follow-up
 CTUs sending out duplicate requests for data
 Differing follow-up schedules between trials and
with routine practice
 CTUs requiring the follow-up date is brought back
in line with date of randomisation
 Difficulty (and/or cost) of retrieving patient notes
(for example, from secure off-site storage facility)
 Consultants telling patients there is no need to follow-
up anymore, but then the trial insists on long term
follow-up and therefore, the patient gets worried
 Postage/photocopying/telephone costs
Issues with electronic follow-up collection – key themes
 Passwords – remembering them, losing them, staff
going off sick and so forth
 Varying software/database quality Lack of training
 Firewalls
 Internet connectivity/network issues
 Electronic CRFs designed badly/too restrictive (for
example, too many checks/not allowing missing data)
 Not accessible in clinic
 Lack of paper trail/back-ups
 Lack of computers/access to internet/space for
personal computers
 Lack of IT support
 Security/data protection/quality assurance/
information governance issues
 Electronic CRFs are time consuming to complete
 UK compatability (for example, Scotland versus
England)
Standard long-term follow-up case report forms
Feedback from the protocol and CRF review and site
questionnaire contributed to the development of a stand-
ard LTFUP CRF that was endorsed by the NCRI Breast
Cancer Study Group in September 2010 for use in current
and future breast cancer trials to alleviate immediate chal-
lenges (Figure 4). The form was designed to be completed
annually around the anniversary of patient entry into the
trial (at randomisation) but with an unrestricted time win-
dow. It was supplied as a word document for electronic
completion or it could be printed out and, given the data
items included on the form, it was intended that there
would be no need for additional relapse/death forms.
Guidance notes accompanied the form to aid completion
and maximise consistency of reporting. The form allowed
the option for patients to be also contacted by telephone
subject to approval within the trial and participating NHS
Trust.
Feedback obtained approximately 1.5 years after en-
dorsement of the CRF indicated that three trials that
were part of the review have either adopted the form as
it was created or produced a modified version based on
its template; three CTUs stated that had not discussed
using it for the specific trials in question but would
consider using the form in future in the absence of an
alternative to site-based data collection.
Discussion
In breast cancer trials, the volume of activity associated
with follow-up and subsequently LTFUP data collection is
a significant and immediate challenge to trialists and to
NHS participating sites, yet with breast cancer patients
remaining at risk of relapse and subsequent death from
their disease 15 years after diagnosis, the clinical require-
ment to collect this information is evident [2-5]. The
protocol and CRF review conducted within this project
showed that the frequency of LTFUP data collection has
been consistent across trials, although earlier follow-up
Figure 4 Long-term follow-up form. Simple one page CRF for collection of primary and secondary efficacy endpoints.
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haps too unnecessarily frequent. Few trials have collected
LTFUP data more frequently than annually and a new trial
would need to justify an increase to this frequency given
the resource implication. The review together with the
questionnaire to sites also confirmed that some data items
can be collected more easily than others; for example, as
may be expected, recurrence and death details were more
accessible than incidence and severity of AEs. Long-term
side effects appear to be the most difficult to collect effi-
ciently and systematically, yet are extremely important to
help our overall understanding of these interventions.
Variation exists with respect to detail of LTFUP infor-
mation collected across trials, influenced by the coordin-
ating CTU. This has resource and funding implications
for both participating hospitals and CTUs. Many clinical
trials recruit UK-wide, and for some trials access to
registry data is already requested although this has his-
torically required access to several routine data sources
given there has not been a single point of access for such
data. In addition, Cancer Registries have been known to
have a significant lag-time for receiving data. Historic-
ally, this has been approximately 18 months from the
event occurring, while for a clinical trial with site-based
follow-up the lag-time is approximately 6 months (on
average) for LTFUP data. While these issues are being
resolved, CTUs are encouraged to standardise data col-
lection across trials by adopting the use of a standard
CRF. The CRF developed as part of this project was de-
signed to be simple and flexible whilst efficiently collect-
ing the data required for the primary and secondary
efficacy endpoints.
Whatever the method used to collect LTFUP data, it is
necessary to be able to correctly identify patients and
obtain appropriate permissions to follow their progress
through routine data sources. The unique NHS/Com-
munity Health Index (CHI) number provides the ability
to track patients throughout the UK, and thus is used as
the primary identifier in registry datasets. Despite this
we found only half of the trials in the review were
collecting NHS/CHI numbers. We urge all investigators
to collect NHS/CHI numbers routinely in clinical trials
and to ask for patients’ consent to use routine data
sources for LTFUP at the time of trial entry.
Given the mode of distribution of the LTFUP ques-
tionnaire to participating sites, via NCRN and its Re-
search Network Manager network, it is not possible to
easily determine the observed response rate. What is
known, however, is the typical number of NHS sites par-
ticipating in the large adjuvant breast cancer trials which
is usually in the region of 100 to 120 NHS sites.
Returned questionnaires from 66 sites would thus indi-
cate a response rate in the region of 50%. This would
imply a broad range of sites responded to the surveyand, therefore, it is reasonable to assume that the main
concerns all sites participating in EBC RCTs have with
LTFUP have been identified. Feedback from participating
sites via the LTFUP questionnaire identified common
concerns, with workload and communication with CTUs
being the main issues.
The ongoing necessity to ascertain information in the
long term relating to patients entered into large cancer
trials requires researchers to explore alternative methods
for data collection. One such method, likely to be of
increased utility given improvements in technology, is to
seek to access routinely collected data to improve reli-
ability of, for example, hospitalisations for long term
AEs. The National Cancer Data Repository (NCDR), de-
veloped by the National Cancer Intelligence Network
(NCIN) since this project was conducted, is one such
dataset that allows each English patient’s treatment path-
way to be mapped from diagnosis to cure or death by
combining key data from cancer registries and Hospital
Episode Statistics (HES). It has been possible to match data
collected as part of the Conventional versus Laparoscopic-
Assisted Surgery in Colorectal Cancer (CLASICC) clinical
trial in colorectal cancer to the NCDR and obtain treat-
ment and outcome data [6]. A similar project has been
completed using the TACT breast cancer trial to see if it
possible to identify trial patients in the NCDR dataset, to
monitor their progress and detect any detrimental effects
from their cancer treatment that may have not been previ-
ously identified [7]. The capabilities of such a method of
LTFUP data collection in Scotland were also assessed for
the TACT trial [8]. Results from the TACT projects indi-
cate that data relating to disease recurrence - an essential
component of the trials included in this review - are not
yet reliably ascertainable via routine sources and that
site-based follow-up is still required. More recently,
other routine cancer datasets have become available
including the Systemic Anti-Cancer Therapy dataset,
National Radiotherapy Dataset, and the Cancer Outcomes
and Services Dataset (COSD). COSD replaces the previous
National Cancer Dataset as the new national standard for
reporting cancer in the NHS in England and was imple-
mented in January 2013. These datasets combined with
the existing HES data greatly increase the potential offered
by the NCIN by including more detail on cancer treat-
ments and reporting of disease relapse.
Meta-analyses of trials continue to offer the most ro-
bust estimates of safety and long-term survival out-
comes. Breast cancer trialists have been at the forefront
of such work via the Oxford based Early Breast Cancer
Trialists’ Collaborative Group and it is important that
the UK is in a position to continue to contribute to these
and other analyses. Using routine datasets to collect
LTFUP information on trial patients should offer the
greatest potential here; however, validity and reliability
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assurances are in place, use of routinely collected data,
which enables trial data to be complemented with
population-based data, will enable wider comparison of the
characteristics of patients participating in trials with the
general population and analysis of other disease and co-
morbid outcomes such as incidence of cardiac disease.
Conclusion
Many of the newer trials on the NIHR breast cancer port-
folio are in smaller, more targeted populations and/or with
short-term endpoints; thus, fewer patients will - in the
future - require LTFUP. However, due to the common
incidence of the disease and the recognised scientific im-
portance of questions to be addressed via large pragmatic
trials, follow-up still has the potential to be a considerable
burden for participating hospitals, CTUs and research
funders. Improved communication and data processes
between CTUs and participating sites will help manage
the workload, whilst improvements in access to routine
data sources for CTUs are welcome. Full use of routine
datasets for trial-related activities remains an aspiration;
however, with the correct systems in place it is hoped that
it can be met within the next 5 years.
Additional file
Additional file 1: Figure A1. Protocol and case report form (CRF)
review data extraction proforma. Figure A2. Questionnaire sent to
participating sites. Figure A3a. Patient identifiers and tracing patients in
the long term. Key patient identifiers and percentage of national trials
collecting each type. Figure A3b. Collection of National Health Service
(NHS) number in relation to year the trial opened for recruitment.
Figure A4a. Frequency of long-term follow-up by type of trial (1-2 years
post-randomisation). Figure A4b. Frequency of long-term follow-up by
type of trial (2-5 years post-randomisation). Figure A4c. Frequency of
long-term follow-up by type of trial (5-10 years post-randomisation).
Abbreviations
AE: adverse event; CHI: Community Health Index; COSD: Cancer Outcomes
and Services Dataset; CRF: case report form; CTU: Clinical Trials Unit;
EBC: early breast cancer; GP: General Practitioner; HES: Hospital Episode
Statistics; LTFUP: long-term follow up; NCDR: National Cancer Data
Repository; NCIN: National Cancer Intelligence Network; NCRI: National
Cancer Research Institute; NCRN: National Cancer Research Network;
NHS: National Health Service; NIHR: National Institute for Health Research;
RCT: randomised controlled trial; TACT: Taxotere as Adjuvant Chemotherapy.
Competing interests
The authors declare that they have no competing interest.
Authors’ contributions
LSK: conception and design of the study, statistical analysis and drafting the
manuscript. JB: coordinating data collection and entering data. JMB:
providing advice on design and statistical analysis and in drafting the
manuscript. All authors read and approved the final manuscript.
Acknowledgements
The authors would like to thank the NCRI Breast Clinical Studies Group for
supporting this project, the NIHR Cancer Research Network Coordinating
Centre for providing funding for this project, the clinical trials units who
provided the protocols and CRFs for review, the research network managerswho facilitated distribution and completion of the participating site
questionnaire and the staff at participating sites who returned the
completed questionnaires.
Received: 26 February 2014 Accepted: 9 September 2014
Published: 27 September 2014
References
1. CRUK Cancer Statistics. [http://info.cancerresearchuk.org/cancerstats/
mortality/cancerdeaths]
2. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG): Effects of
radiotherapy and of differences in the extent of surgery for early breast
cancer on local recurrence and 15-year survival: an overview of the
randomised trials. Lancet 2005, 366:2087–2106.
3. Early Breast Cancer Trialists’ Collaborative Group (EBCTG): Effects of
chemotherapy and hormonal therapy for early breast cancer on
recurrence and 15-year survival: an overview of the randomised trials.
Lancet 2005, 365:1687–1717.
4. Barrett SV, Dewar JA, Nan H, McEleney T, Bliss J, Kilburn L, Brewster DH:
Can Linkage to Routinely Collected Health Records Substitute for Active
Follow-Up of Clinical Trial Participants? In Proceedings of the 34th
International Association of Cancer Registries Conference. Cork, Ireland: 2012.
5. Bliss JM, Ellis P, Kilburn L, Bartlett J, Bloomfield D, Cameron D, Canney P,
Coleman RE, Dowsett M, Earl H, Verril M, Wardley A, Yarnold J, Ahern R,
Atkins N, Fletcher M, McLinden M, Barrett-Lee P: Mature analysis of UK
Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects
of treatment and characterisation of patterns of breast cancer relapse.
Cancer Res 2012, 72(24 Suppl 3):Abstract P1-13-03.
6. Gray RG, Rea D, Handley K, Bowden SJ, Perry P, Earl HM, Poole CJ, Bates T,
Chetiyawardana S, Dewar JA, Fernando IN, Grieve R, Nicoll J, Rayter Z,
Robinson A, Salman A, Yarnold J, Bathers S, Marshall A, Lee M, on behalf of
the aTTom Collaborative Group: aTTom: long-term effects of continuing
adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953
women with early breast cancer. J Clin Oncol 2013, 31(Suppl):Abstract 5.
7. Morris EJA, Jordan C, Thomas JD, Cooper M, Brown JM, Thorpe H, Cameron
D, Forman D, Jayne D, Quirke P, in collaboration with the CLASICC trialists:
Comparison of treatment and outcome information between a clinical
trial and the National Cancer Data Repository. British J Surg 2011,
98:299–307.
8. Kilburn L, Aresu M, Banerji J, Bliss JM: Results of a Retrospective Linkage of
TACT (CRUK 01/001) Breast Cancer Trial Data and the National Cancer
Data Repository. In Proceedings of 10th National Cancer Research Institute
(NCRI) Cancer Conference. 4-7 November 2012, Liverpool, UK. Abstract A141.
Available from: http://conference.ncri.org.uk/abstracts/2012/abstracts/A141.html.
doi:10.1186/1745-6215-15-379
Cite this article as: Kilburn et al.: The challenges of long-term follow-up
data collection in non-commercial, academically-led breast cancer
clinical trials: the UK perspective. Trials 2014 15:379.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
